¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º E )2/Vn2  
<N3~X,ch  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ ;ULw-&]P  
Nz%pl!  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) @X=sfygk  
ch0cFF^]  
1. ICAM-1 3K/]{ dkD  
fG{3S:TQq  
2. interleukin 12(IL-12) "#iO{uMWb  
h]IoH0/  
3. tumor infiltrating lymphocyte }r"E\~E  
yA7O<p+  
4. TCR/CD3 complex Y^|15ek  
V9%9nR!'  
5. hematopoietin receptor family SCfk!GBVD  
=PnNett}a  
6. individual idiotype(IdI) 0BAZWm  
IWwOP{ <ZQ  
7. integrin f/Z-dM\e  
ZvK 3Su)f1  
8. colony-stimulatory factor (CSF) A.YK=_J  
{3!A \OR  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© h645;sb0  
0t*PQ%  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? x/0x&la  
OSom-?|w  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ =YtK@+| i  
:73T9/  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠEh"Y<]$  
"#{b)!EH  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ t=[/ L]!  
1o)<23q`)  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) JBISA _Y  
Z(J 1A x  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ 4dh> B>Q  
jank<Q&w  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) ubsx NCqD  
TdoH(( nY  
3. immunoglobulin superfamily (IgSF) bnE&-N*  
QKoJxjR=^  
4. selectin rPHM_fW(O@  
[c99m:*+  
5. anti-idiotypic antibody (¦ÁId) V{rQ@7SE  
 yT(86#st  
6. major histocompatibility complex(MHC) HaOSFltf#  
ork{a.1-_w  
7. immunotolerance **ls 4CE<  
I*(7(>zgyv  
8. biological reponse modifier(BRM) nYK!'x$  
i2\CDYP  
9. immune reponse gene (Ir gene) g#5t8w  
R LDu5  
10. reshaped antibody (or reconstituted antibody) _cbXzSYq&  
AgdU@&^  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 0LP>3"Sm  
1mx;b)4t  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ JOki4N  
*(VwD)*  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? xf{=~j/L  
a#3,qp!  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£  VO*fC  
A E%zqvp>  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? ~hU^5R-%  
}i\_`~  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ QFEc?sEe  
By0Zz  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? cLMFC1=b  
"o<&3c4  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ e73zpF  
"3NE%1T  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ x4@IK|CE  
5%R$7>`Z  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? x]:B3_qR  
!p4FK]B/u  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ q.p.y0  
W; ?'  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: /909ED+)>9  
TfFH!1^+  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: lQer|?#  
>2< Jb!f&  
ÃâÒßѧ Iy {&T#e"  
B,ZLX/c9  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© I~7eu&QZ  
}m-+EUEo9  
1. CD8 d##'0yg   
[Ma d~;  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) ZCCwx71j  
KEvT."t  
3. immunoglobulin fold(Ig fold) {@`Z`h" N  
z T#j.v  
4. cadherin (Ca-dependent cell adhesion moleculers) ,W~a%8*  
RU GhhK  
5. idiotype-anti-idiotypic antibody immune network theory h8tKYm  
0%<x>O  
6. HLA class II antigen <YBA 7i  
 -!z,t7!  
7. complementarity-determining region (CDR) ^H UNq[sQ  
gdyP,zMD7  
8. perforin(or pore-forming protein ,PFP) 'Ijjk`d&c  
Z'L}x6  
9. high affinity IL-2 receptor _,;|,  
^8r4tX  
10. artificial active immunization  7ehs+GI  
VXtW{*{"  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 4RV5:&ALLS  
DU/WB  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ@ \(*pa  
vo_m$/O  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 O0i[GCtP5  
{ f @k2^  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ H%:~&_D  
1 ]uHaI(  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ =c,m)\u/8  
"`AIU}[_I  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ cR+9^DzA  
;nbUbRb  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? _ ecKX</Q  
cDS6RO?  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ]#N~r&hmQ  
9_mys}+  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ PKhH0O\_U  
'K=n}}& :  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 0b0.xz\~U  
csV.AN'obq  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ]$'w8<D>t,  
Vb `m3  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© R&BbXSIDX  
R30{/KK  
1. immunoglobulin gene rearrangement _[8BAm  
!'()QtvC<  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) q1Vh]d  
YH( 54R  
3. flow cytometry(FCM) :66xrw  
t c%?{W\  
4. carrier effect %.kJ@@_e  
QQ4  &,d  
5. positive selection of T lymphocytes in thymus :bx q%D%|o  
` gIlS^Q  
6. mouse TH1(Th1) and TH2(Th2) subsets /h=:heS4$  
\lVxlc0{?  
7. perforin (pore-forming protein ,PFP) UC)-Fd  
7tgn"wK  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) }5Yd:%u5  
n22k<@y  
9. SH-2(src-homology region 2) -,NiSh}A  
sM)n-Yy#9  
10. Ab2¦Â (internal image) m&xyw9a  
@G  0k+  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© qk pnXQ  
gbOd(ugH  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? RkVU^N"  
,/n<Qg"`  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? L4I1nl  
KlbL<9P >  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠiGmBG1a\  
*k:Sg*neVq  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ Xk[;MZ[  
3-4' x2   
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠsr!m   
`z<k7ig  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) {7!WtH;-  
,"!t[4p=f  
ÃâÒßѧרҵ£º FBpf_=(_1  
6]#pPk8[Z  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ d4h1#MK  
`~'yy q  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? {S4^;Va1  
3*9<JHu  
´«È¾²¡Ñ§×¨Òµ£º %;+Q0 e9  
U5 ~L^  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ }r:H7&|&  
c` ^I% i  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ )N!-g47o%#  
?k)(~Y&@p  
Ïû»¯×¨Òµ£º dx{ZG'@aH  
-}nTwx:|5u  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ FV|/o%XqK  
bgs2~50  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? KF&1Y>t=  
HhkubG)\  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ |U}al[  
__jFSa`at  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© l!z0lh- J  
sr(f9Vl  
1. Fas(CD95)/FasL ,<]X0;~oB  
N- E)b  
2. common chain of cytokine receptor |`d5Y#26  
B 14Ziopww  
3 . TCR/CD3 complex \yeo-uN8  
/lBx}o'  
4. negaive selection of thymocytes L$*sv .  
 Qx,jUL#2  
5. artificial active immune G5~ Jp#uA  
r |[uR$|Y  
6. anti-idiotypic '{9 nQ DgT  
Y{~[N yE  
7. IgSF Ys|n9pW  
(h;4irfX  
8. Integrin  'Q\I@s }  
k`H#u,&  
9. chemokine I8=p_Ie  
FF]xwptrx  
10. B7/CD28 6J3:[7k=&  
Lw EI   
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© Y0`=h"g  
gc|?$aE  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ |FK ##8  
:]&O  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ uh`W} n  
NbPv>/r  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ /ekeU+j  
$ekJs/I&  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ d;GF<bz  
HFV4S] U=  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ M~ =Bln5  
D@5Ud)_  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ 8*O ]   
}*4K{<02  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 7v9l+OX,6  
I7!+~uX  
1. B7/CD28 US<bM@[  
|)4Fe/!cJ  
2. Th1 subset `Mj>t(  
UA@(D  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© H^UuT  
~";GH20  
4. antibody affinity maturation i"eUacBz/-  
j<+Q Gd%  
5. AP-1 F' eV%g  
v6r,2Va/  
6. single chain variable fragment£¨ScFv£© "AH1)skB:  
i9KQpWG:  
7. NK cell receptor  U/v }4b  
4.?tP7UE  
8. Zinkernagel-Doherty phenomenon zoFCHs r  
:u}FF"j  
9. Ig fold /%W&zd=%#  
%`rZ]^H  
10. CD40/CD40L rnB-e?>  
|UA)s3Uhxb  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© ,MH9e!  
1 +P&O4>  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ P2lDi!q|  
xx^7  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 37:\X5)z/  
lO?dI=}]  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ nYfZ[Q>v  
)~((6?k4e  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ ?f9@  
9rO,h|L   
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ )vO?d~x|  
okl*pA)  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ N~<H`  
@@&([f  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ G}MJWf Hl  
'"# W!p  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© e MX?x7  
&f 2'cR  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ^o`;C\  
jrOqspv   
1.Co-stimulators (or co-stimulating molecules) AD_aI %7  
j?5s/  
2.NK-kB +:JyXF u  
wOhiC$E46  
3.Immunoglobulin superfamily @vy {Q7aM  
5*Wo/%#q  
4.antigen-presenting cell (APC) U{^~X_?  
v6Vd V.BI  
5.death domain ,-55*Rbi  
n"p|tEK  
6.CCR and CXCR #&L[?jEn  
9_~[  
7.Lectin (or mitogen) yA74Rxl*6  
> 4c7r~\k  
8.Clusters of differentiation, CD) YPq4VX,  
C(RZ09,.S  
9.B7 family sYt\3/yL'  
"s:eH"_s  
10.Cytotoxic T lymphocyte, CTL) o~ v   
Z= 'DV1A$,  
11.IL-15 and IL-15 receptor (IL-15R)  k|Xxr  
R F)Qsa  
12.MHC restriction  .<0s?Q  
f{} zqCK  
13.Affinity-chromatography 3 &aBU [  
Lc0 U-!{G  
14.Cyctosprin A, CsA BdK2I!mm  
U',.'"m  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) r-r)'AAO  
TA x9<'  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© .e^AS~4pl  
@[:JQ'R=  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 =p1aF/1$I  
gK`o ;` ^  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 4 ^=qc99  
(|{bZW}  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ N 33{vx  
`]+-z +  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ]~')OSjw  
nE~HcxE /  
ÃâÒßѧרҵ£º SP&Y|I$:  
3?}W0dZ$d  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ ^/)!)=?  
E yv|~D  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ M~6x&|2  
@YH<Hc  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ #4?(A[]>H  
Kb<^Wdy4T  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) z3RlD"F1  
l~Em2@c  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) *\UxdL 22  
Uf:G,%OYi  
1. ADCC(antibody dependent cell-mediated cytotoxicity) ]h Dy]  
v4:g*MD?~  
2. »·æß¾úËØ(cyclosporin) !PaDq+fB  
7\BGe I  
3. KIR(killer cell inhibitory receptor) CoZXbTq  
LPg1G+e  
4. HLDA(human leucocyte differentiation antigen) ?pT\Ft V  
pB3dx#l  
5. Interleukin 18(IL-18) "S">#.L  
<lx~/3<m  
6. ÕûºÏËØ(integrin) UE3#(:x A  
9Q!X~L|\S  
7. Fas/FasL jY]hMQ/H  
8a\ Pjk  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) B!Ss 35<  
OV l,o  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) ;K'1dsA  
(HHVup1f  
10. Th1/Th2 6j]pJ]F6  
'qosw:P  
11. »ùÒòÒßÃç(DNAÒßÃç) SI:+I4i  
S?Y,sl+A:  
12. chemokines and chemokine receptor N6GvzmG#g  
]M"l-A  
13. ÃâÒßÄÍÊÜ G3j&8[  
x5Sc+5?*  
14. ¹²´Ì¼¤·Ö×Ó ,j4 ;:F  
w$JG:y#  
15. ËÀÍö½á¹¹Óò(death domain) !l7eB@O  
!MOgM  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) XO)|l8t#$=  
bK)gB!  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? a95QDz  
@v1f)(N  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠRt$Q *`u   
MIcF "fB![  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î `+~@VZ3m  
l vuoVINEp  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ H];QDix?  
bg\~"  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå Fe(qf>E  
} k[gR I]  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ :/HfMJ  
^-3R+U- S  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) D0?l$]aE  
Ybr&z7# 2  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ P)?)H]J"  
LTsG  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ &H!#jh\w  
\-mz[ <ep  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»